VANCOUVER, BC, Oct. 21, 2026 /PRNewswire/ -- Stock Preachers News Commentary - Three sessions into the week, growth and small caps are setting the pace. The Nasdaq Composite jumped 1.04% on the day and is up 2.14% for the week to 26,700.62, while the Russell 2000 added 0.44% to push its weekly gain to 2.36%. The Dow and S&P 500 are contributing too, both up more than 1.2% for the week, as earnings from industrial, healthcare, exchange and homebuilding names give investors fresh data points to sort leaders from laggards. Active Companies from around the markets with current developments this week include: RTX (NYSE: RTX), Abbott (NYSE: ABT), CME Group Inc. (Nasdaq: CME), M/I Homes, Inc. (NYSE: MHO), and Lockheed Martin (NYSE: LMT).

The Dow Jones Industrial Average closed at 52,637.78, up 0.27% on the day and 1.22% for the week, trading between a weekly low of 51,863.80 and a high of 52,711.93. The S&P 500 rose 0.5% to 7,751.45, up 1.2% for the week with an RSI14 of 53.1, while the Nasdaq's RSI14 sits at 48.6 despite its outsized weekly gain. The Russell 2000's RSI14 of 44.9 trails the pack even as it posted the week's best percentage move.

Volatility eased alongside the rally. The VIX closed at 16.72, down 0.59 on the day and 1.72 for the week, while the Nasdaq-100 Volatility Index fell to 24.65, down 2.48 for the week. Both gauges sit near their weekly lows of 16.51 and 23.92, respectively, suggesting hedging demand has cooled as equities climbed.

Commodities told a different story. WTI crude tumbled 4.64% on the day and 6.36% for the week to $97.07 a barrel, and natural gas dropped 4.79% on the day and 7.75% for the week to $2.82 per MMBtu. Gold edged up 0.18% to $4,150.10 an ounce, silver gained 1.18% for the week to $57.65, and the 10-year Treasury yield held near 5.11%, up 1 basis point for the week.

The full report lays out the key support and resistance levels for each index along with a broader look at the week's corporate players and sentiment heading into the final sessions.

CONTINUED... Read this and more news for RTX (NYSE: RTX), Abbott (NYSE: ABT), CME Group Inc. (Nasdaq: CME), M/I Homes, Inc. (NYSE: MHO), and Lockheed Martin (NYSE: LMT) at: https://stockpreachers.com/articles/tech-carries-the-tape-as-midweek-leaders-pull-away-from-the-pack/

In other industry developments and happenings in the market this week include:

RTX (NYSE: RTX) RTX reported third quarter sales of $25.0 billion, up 11 percent versus the prior year and up 12 percent organically. Adjusted EPS of $2.26 rose 33 percent year over year, including $0.25 from IEEPA cost recovery. The company's backlog reached a record $340 billion, split between $176 billion commercial and $164 billion defense.

The company raised its full year 2026 outlook, now guiding adjusted sales of $97.0 to $97.5 billion, up from $95.0 to $96.0 billion, and adjusted EPS of $7.65 to $7.75, up from $7.10 to $7.25. Free cash flow guidance moved to $9.0 to $9.2 billion from $8.50 to $8.75 billion.

"Our strong execution and operational focus in the third quarter enabled RTX to deliver double-digit organic sales growth across commercial aerospace and defense," said RTX Chairman and CEO Chris Calio. "Demand for our products remains robust with over $81 billion of new commercial and defense awards, resulting in a record backlog of $340 billion." Read the release.

Abbott (NYSE: ABT) Abbott posted third quarter reported sales growth of 14.5 percent and comparable sales growth of 7.0 percent. GAAP diluted EPS came in at $0.53, while adjusted diluted EPS reached $1.42, excluding specified items.

The company reaffirmed the midpoint of its full year 2026 adjusted diluted EPS guidance and tightened the range to $5.50 to $5.55, while projecting full year comparable sales growth of approximately 6.0 percent. Abbott also highlighted several new product approvals during the quarter, including FDA approval for its Libre Duo dual glucose-ketone biowearable sensor and CE Mark for its Amulet 360 Left Atrial Appendage Occluder.

"Abbott delivered strong third-quarter results, reflecting balanced growth across our portfolio," said Robert B. Ford, chairman and chief executive officer, Abbott. "With strong performance across multiple businesses and a robust pipeline of innovation, we are well-positioned to deliver sustainable growth in the years ahead." Read the release.

CME Group Inc. (Nasdaq: CME) CME Group reported third quarter revenue of $1.7 billion and operating income of $1.1 billion, with net income of $1.0 billion and diluted earnings per share of $2.89. On an adjusted basis, operating income was $1.2 billion, net income was $1.1 billion and diluted EPS was $3.02.

Average daily volume climbed to a third-quarter record of 29.4 million contracts, with non-U.S. ADV reaching a third-quarter high of 9 million contracts. Market data revenue hit a record $243 million, up 20 percent. The company returned nearly $1 billion to shareholders in the quarter, including $465 million in dividends and $524 million in share repurchases.

"As uncertainty intensified in Q3, clients turned to CME Group in record numbers to manage risk and capitalize on opportunities," said CME Group Chairman and Chief Executive Officer Terry Duffy. "With double-digit volume growth across all six asset classes, Q3 was our second highest quarter ever for revenue and adjusted net income." Read the release.

M/I Homes, Inc. (NYSE: MHO) M/I Homes reported third quarter revenue of $1.1 billion, down 5 percent, with homes delivered declining 2 percent to 2,241 and new contracts falling 2 percent to 1,861. Net income was $67 million, or $2.56 per diluted share, compared with $107 million, or $3.92 per diluted share, a year earlier.

Gross margin came in at 20.9 percent, or 21.3 percent excluding inventory charges. Shareholders' equity reached a record $3.3 billion with book value per share rising to a record $130, and the company repurchased $50 million of common stock while maintaining a homebuilding debt to capital ratio of 18 percent.

"Our third quarter results reflect increasingly difficult market conditions, including higher mortgage interest rates, weaker demand and growing economic uncertainty," said Robert H. Schottenstein, Chief Executive Officer and President. "Notwithstanding these conditions, we produced fairly solid results generating $87 million of pre-tax income, equating to an 8% return." Read the release.

Lockheed Martin (NYSE: LMT) Lockheed Martin delivered a C-130J-30 Super Hercules aircraft to the U.S. Navy at its Marietta, Georgia facility, marking the start of its conversion into the E-130J Phoenix II, the Navy's next-generation TACAMO airborne nuclear command and control platform.

The aircraft will be transferred to Northrop Grumman, the mission systems integrator, to complete the conversion. The delivery re-establishes a link to the Hercules family's TACAMO history, following the EC-130Q variant that flew the mission from 1963 to 1993.

"This delivery marks a historic milestone for the U.S. Navy, Lockheed Martin, and the nation's strategic communications network," said Trish Pagan, vice president of Lockheed Martin's Air Mobility & Maritime Missions. "It is built to deliver the capabilities our joint force demands and built to last through any operational challenge." Read the release.

Contact Information:

Media Contact: [email protected]

DISCLAIMER: Nothing in this article should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a market commentary and is not a paid advertisement. This article is being distributed by Stock Preachers, which is wholly owned and operated by Market Equities Limited ("MEL"), a company incorporated under the laws of Ireland. This is an independent market commentary published on a non-paid basis. MEL has not been paid any fee by any company mentioned in this article for its production or distribution, and MEL has no advertising or digital media agreement with any company mentioned in this article. The companies mentioned have not reviewed or approved this article. Market Equities and its owners, operators, directors, and affiliates may, from time to time, hold positions in securities mentioned in this article or in the broad-market index funds that track them, and reserve the right to buy, sell, or hold such securities at any time without further notice. Information in this article was obtained from sources believed to be reliable, including company news releases and public market data, but its accuracy cannot be guaranteed. Market data is as of the time stated and may be delayed. Portions of this commentary were produced with the assistance of automated tools from that data and reviewed against it. Investing in securities involves risk, including the possible loss of some or all of your investment. Technical analysis describes past price and volume behavior and does not predict future results; support and resistance levels can fail at any time. References to the companies named in this article are provided solely as market and sector context and as summaries of each company's own public news releases. No partnership, affiliation, or endorsement is implied, and nothing in this article is a recommendation to buy, sell, or hold any security. Quotations attributed to company executives are reproduced from those companies' own news releases. Forward-Looking Statements: This article may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements made by the companies mentioned in their own news releases. Such statements involve risks and uncertainties, and actual results may differ materially.

Hand to Hold Announces 2026 National NICU Mental Health Conference Program, Invites Parents and Healthcare Professionals to Attend

November 4–5 virtual conference features sessions on trauma-informed care, caregiver burnout, grief and family-centered support led by experts and parents with lived experiences; registration is free for NICU parents.

AUSTIN, Texas, Oct. 21, 2026 /PRNewswire/ -- Hand to Hold, a national nonprofit supporting neonatal intensive care unit (NICU) families, has announced the full program for its 2026 National NICU Mental Health Conference, taking place virtually November 4–5. The two-day event features expert speakers, personal perspectives and practical strategies to strengthen mental health support for families and healthcare teams.

Experience the full interactive Multichannel News Release here: https://www.multivu.com/hand-to-hold/9360851-en-hand-to-hold-2026-national-nicu-mental-health-conference-program

Building on these important conversations, keynote speakers Gigi Khonyongwa-Fernandez, a trauma-informed leadership coach, and J.S. Park, a hospital chaplain and author, will share insights on compassion, navigating grief and finding healing.

"Families and healthcare professionals carry the emotional impact of the NICU long after a hospital stay ends," said Katrina Moline, executive director of Hand to Hold and a NICU graduate parent. "We designed this conference to turn important conversations about mental health into practical action."

Sessions include:

- What If Compassion Came First?: Why being seen matters more than having all the answers

- Operationalizing Trauma-Informed Care through Partnering with Individuals with Lived Experience

- Beyond the NICU: The Intersection of Unexpected Diagnoses, Long-Term Care, and Mental Health

- Caring for Others Without Losing Yourself: A Practical Primer for NICU Families and NICU Professionals

- The Many Faces of Grief: Understanding and Supporting Families through Loss

- Sensory Wellbeing Guide: Practical Sensory Strategies for Neonatal Staff

- Collaborating with Parents for a Healthier Outcome

- More Than A Visitor: A NICU Dad's Experience

The conference will also recognize outstanding contributions to the NICU community through the NICU Hero Awards, sponsored by Keenova.

Registration is open, with free attendance for NICU parents and continuing education credits available to NICU professionals for all conference sessions. Register at HandToHold.org/conference.

About Hand to Hold

Hand to Hold® is a national nonprofit 501(c)(3) organization dedicated to providing early-intervention mental health support, educational resources, and community for parents before, during, and after a neonatal intensive care unit (NICU) stay. Our services are offered at no cost to families and are tailored to meet the emotional and mental health, physical and social needs of NICU parents. Our support staff comprises NICU graduate and bereaved parents with specialized training. For more information, visit HandtoHold.org.

Media Contact:

Lauren Brown

[email protected] 

SOURCE Hand to Hold

Share this article

Therakos Receives MDR Approval in Europe for Treating Immune-Related Adverse Events in Patients with Inadequate Response to Corticosteroids

DUBLIN, Oct. 21, 2026 /PRNewswire/ -- Therakos Development Limited, a global pioneer in immunomodulatory therapy delivered at the bedside through extracorporeal photopheresis (ECP), announced today that its THERAKOS™ CELLEX™ Photopheresis System has received certification under the EU MDR for an expanded indication. The system is now indicated in Europe for the treatment of immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI) therapy in adults who have had an inadequate response to corticosteroids. It is the first and only therapy approved for this use anywhere in the world.

ICI therapy has transformed cancer care by harnessing the immune system to deliver durable antitumor responses. However, this same immune activation can trigger potentially severe irAEs, compromising treatment continuity and patient outcomes. Corticosteroids remain the standard initial treatment for clinically significant irAEs, often requiring interruption or discontinuation of ICI therapy. For patients who do not respond adequately, additional immunosuppressive treatments may be necessary, potentially further compromising antitumor immunity. These challenges underscore a critical unmet need for therapeutic approaches that effectively manage immune-related toxicities while preserving the benefits of cancer immunotherapy.

"The management of steroid-refractory irAEs remains a challenge since data on effectiveness of different drugs is scarce and immunosuppression can hinder antitumor response. The THERAKOS™ CELLEX™ Photopheresis System, which is now approved for this indication in Europe, represents a significant advancement in treatment of steroid-refractory irAEs," said Prof. Dr. Lucie Heinzerling, MPH, Professor of Dermatology and Venereology, LMU University Hospital, Ludwig Maximilian University.

"At Therakos, we are committed to addressing the needs of patients who are impacted by immune-related complications of ICI therapy," said Sandra Thompson, Co-Chief Executive Officer, Therakos. "As the first and only therapy approved to treat these complications, the THERAKOS™ CELLEX™ Photopheresis System gives European medical oncology teams an important new option for treating their patients."

ECP takes a different approach than traditional options. Rather than broadly suppressing the immune system, it is designed to help re-establish immune balance using the patient's own cells. The goal is to address the toxicity without broad immunosuppression. It is well established that immunosuppression can compromise the cancer therapy itself.

"Immune-related toxicity has long been treated as a systemic problem, but it's better understood as a tissue-specific one. ECP resolves inflammation at the site where it occurs, through the body's own anti-inflammatory signaling, rather than suppressing the immune system broadly. As immunotherapy reaches more patients and more combinations, managing its toxicity without compromising its benefit will define how far the field can go. This expanded indication in Europe puts a therapy that does exactly that in clinicians' hands," said Prof. Dr. Robert Zeiser, Professor of Medicine and Director of the Division of Tumor Immunology at the Department of Hematology, Oncology, and Stem-Cell Transplantation at the Medical Center University of Freiburg.

Clinicians can access the THERAKOS™ CELLEX™ Photopheresis System for irAEs associated with ICI therapy in adults who have had an inadequate response to corticosteroids through an existing network of over 190 centres in Europe as a result of this MDR approval.

About Therakos

Therakos is a global pioneer in autologous immunomodulatory therapy delivered at the bedside through Extracorporeal Photopheresis (ECP). Supported by more than four decades of clinical experience and evidence-based medicine, the Therakos ECP system was among the first FDA-approved cell-based immunomodulatory therapies. Our mission is to restore and protect human immunity. Rather than broadly suppressing the immune system, our approach is designed to help re-establish immune balance by harnessing the power of a patient's own cells. Through ongoing investment in research, evidence generation, and innovation, we are advancing the science of immunomodulation to expand understanding and improve outcomes for patients living with complex immune-mediated diseases. Learn more at https://therakos.eu/

About Extracorporeal Photopheresis (ECP)

ECP is an immunomodulatory therapy delivered at the bedside. A small volume of the patient's white blood cells is collected, treated with a photoactive agent and ultraviolet A light, and returned to the patient. Rather than broadly suppressing the immune system, ECP is designed to help re-establish immune balance using the patient's own cells.

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ CELLEX™ PHOTOPHERESIS SYSTEM

Indications

As certified in the EU, the THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

- Cutaneous T Cell Lymphoma (CTCL)

- Solid Organ Transplant Rejection (SOT) (heart, lung)

- Treatment of immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI) therapy in patients with inadequate response to corticosteroids

The THERAKOS™ CELLEX™ Photopheresis System is also indicated for use in EU MDR jurisdictions in patients older than 3 years of age for the management of:

- Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

The THERAKOS™ CELLEX™ Photopheresis System is contraindicated in:

- Patients possessing a specific history of a light sensitive disease.

- Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³.

- Patients who have coagulation disorders or who have previously had a splenectomy.

Warnings and Precautions

THERAKOS™ CELLEX™ Photopheresis System treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

- Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.

- Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.

- When prescribing and administering THERAKOS™ CELLEX™ Photopheresis System for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

- Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.

- Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.

- Treatment frequency exceeding labelling recommendations may result in anaemia.

- Venous access carries a small risk of infection and pain.

Please refer to the THERAKOS™ CELLEX™ Photopheresis System Operator's Manual for a complete list of warnings and precautions.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS™ CELLEX™ PHOTOPHERESIS SYSTEM

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.

Warnings and Precautions

- Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinoma should be diligently observed and treated.

- Methoxsalen may cause fetal harm when given to a pregnant woman. Women undergoing photopheresis should be advised to avoid becoming pregnant.

- Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.

- Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.

- Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

The THERAKOS® CELLEX® Photopheresis System is not approved by the U.S. Food and Drug Administration (FDA) for the treatment of immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI) therapy in adults who have had an inadequate response to corticosteroids.

Contact

Media enquiries

Debbie Miller, Therakos

[email protected]

©2026 Therakos Development Limited.

TKS-26-00481 Oct 2026

SOURCE Therakos Development Limited

Share this article

Husqvarna Group notes EU Commission's disclosure in robotic mower anti-dumping investigation

STOCKHOLM, Oct. 21, 2026 /PRNewswire/ -- Husqvarna Group has today received the European Commission's disclosure of essential facts and considerations in the ongoing anti-dumping investigation concerning EU imports of robotic lawnmowers originating in the People's Republic of China.

Issuance of the disclosure is a procedural step provided for under EU trade defence law. It is confidential, and Husqvarna Group will not comment on its content. Interested parties, including Husqvarna Group, now have the opportunity to submit comments to the Commission within the deadline it has set. The Commission will consider these comments before reaching its conclusions. The statutory deadline for a decision on definitive measures is 19 January 2027.

Husqvarna Group has confidence in the Commission's process, which is evidence-based and conducted in accordance with EU law and the WTO framework. We remain confident in the substance of the case we have presented and in the evidence submitted, and we will continue to cooperate fully with the investigation.

For additional information, please contact:

Media

Henrik Sjöström, Head of external communication

+46 727 - 15 77 85

[email protected]

Investors

Emelie Alm, Vice President Investor Relations

+46 705 - 14 64 14

[email protected]

Husqvarna Group

Husqvarna Group is a global leader in innovative solutions for managing forests, parks, and gardens, as well as equipment and diamond tools for the construction industry. With an innovative mindset, we are dedicated to delivering high-quality solutions ranging from robotic mowers to chainsaws, watering systems and power cutters, with a strong focus on our customers and future generations.

Founded in the Swedish town Huskvarna in 1689, we have been pioneers in our business for more than three centuries. Today, we are mainly operating under the global Husqvarna and Gardena brands, serving consumers and professionals in over 100 countries through direct sales, dealers, and retailers. Headquartered in Stockholm, Sweden, Husqvarna Group employs approximately 11,900 people in 40 countries and reported net sales of SEK 46.6 billion in 2025. Husqvarna Group is listed on Nasdaq Stockholm.

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

SOURCE Husqvarna Group

Share this article

VANCOUVER, BC, Oct. 21, 2026 /PRNewswire/ -- SAGA Metals Corp.("SAGA" or the "Company") (TSXV: SAGA) (OTCQX: SAGMF) (FSE: 20H), a North American exploration company focused on critical mineral discoveries, is pleased to announce the successful completion of its maiden diamond drill program at the 100%-owned Wolverine Heavy Rare Earth Element Project in Labrador, Canada. The program consisted of 22 diamond drill holes (DDHs) totalling 3,241 metres and represents the first systematic diamond drilling conducted on the property.

The 2026 field program had three primary objectives: (1) execute a maiden diamond drill program to test REE mineralization previously documented by historic reverse circulation (RC) drilling, backpack drilling, and surface sampling; (2) conduct detailed alteration and outcrop mapping in the vicinity of the drill program; and (3) undertake prospecting and rock sampling of additional potentially mineralized areas outside the immediate drill footprint.

Program Highlights

Completion of 22 diamond drill holes totalling 3,241 metres.

Promising alteration assemblage interpreted as related to REE mineralization identified in all 22 holes.

Two holes fully logged and sampled, returning thick intervals of Unit 4 (up to 118.75 m) with extensive alteration from near surface to end of hole.

Prospecting confirmed and expanded the distribution of Units 3, 4, and 5 over a large portion of the property.

New and historic pegmatites and aplite dykes located in the south of the property, significantly expanding the targeted areas.

Early indications of structurally controlled, sub vertical epithermal-style mineralization with potential depth extent.

Diamond Drill Program Details

All 22 holes were drilled at an azimuth of 230° and a dip of -85°. The program focused on an area of known REE mineralization and systematically tested the crystal-poor ash tuff (Unit 4), its upper contact with crystal tuff (Unit 5), and its lower contact with crystal tuff (Unit 3), together with multiple step-out holes. End-of-hole depths ranged from 43 m to 204 m.

Quick logging completed by the on-site geologist identified an alteration assemblage interpreted to be associated with REE mineralization in all 22 holes (see Figure 1 for completed drill holes). To date, two holes have been fully logged and sampled:

W26-001 (182 m total depth): The upper 13.1 m intersected a red quartz-feldspar crystal tuff of Unit 5, which grades into a variable sequence of ash tuff, lithic tuff, ignimbrite, and crystal tuff of Unit 4. Alteration cycles between sericite-dominant and chlorite-dominant intervals, both associated with sulphides. Unit 4 is 118.75 m thick and grades into Unit 3 crystal tuff at 120.55 m, which continues to the end of the hole. Alteration was logged from 1.8 m to the end of the hole (total alteration interval of 180.2 m). 138 core samples were collected.

W26-002 (179 m total depth): The upper 31.9 m is red quartz-feldspar crystal tuff of Unit 5, grading into ignimbrite, ash tuff, and crystal tuff of Unit 4. Alteration switches between sulphidic, chloritic, and sericitic intervals. Unit 4 is 50.97 m thick and grades into beige crystal tuff of Unit 3 by 82.87 m, which continues to the end of the hole. Alteration was logged from 0.35 m essentially to the end of the hole (total alteration interval of approximately 178.65 m). 139 core samples were collected.

Logging and sampling of the remaining 20 holes are in progress. Assay results from the fully sampled holes are pending. The Company anticipates receiving and reporting initial assay results in batches in due course.

Prospecting and Rock Sampling

Prospecting was conducted during the diamond drill program over a two-month period across other portions of the Wolverine property. A total of 136 grab samples were collected (see Figure 2 for sample locations); assays are pending. Units 5, 4, and 3 were identified in multiple locations across the property, indicating that the prospective volcanic sequence has significant lateral extent and that future drilling can be meaningfully expanded beyond the 2026 drill footprint.

Scintillometer-supported prospecting in the southern part of the property confirmed the presence of multiple previously identified pegmatites and resulted in the discovery of numerous new pegmatites and aplite dykes (See Figure 3).

Alteration-structural observations

Preliminary observations from core and outcrop support the interpretation that the REE mineralization is hosted within a propylitic (chlorite-dominant) alteration zone developed in Units 3, 4, and 5 (Figure 4) Limited intervals of argillic alteration Chloritization occurs both as pervasive replacement of the volcanic rocks and is accompanied by chlorite+sulphide+REE-bearing carbonate-bearing veins, fractures and breccias oriented at various angles to the core axis. Notably, many of the more significant fracture and breccia domains are oriented parallel to sub-parallel to the core axis. Given the steep inclination of the drill holes, these fracture-breccia structures are interpreted as sub vertical hydrothermal feeder structures that formed stratiform-like alteration zones in volcanic units 5, 4 and 3. These structurally-controlled, sub vertical fracture-breccia networks have the mineralogical attributes that unequivocally indicate formation from a volatile-rich magmatic-hydrothermal fluid derived from an overpressured hydrothermal reservoir related to peralkalaine intrusions.

Next Steps

The Company will complete logging and sampling of the remaining holes and submit samples for assay. Detailed mapping data will be fully analysed and integrated with the drill results. An induced polarization (IP) survey is planned for Q2 2027; interpretation of the IP data, combined with the 2026 geological and assay results, is expected to guide a follow-up drill program targeting the downward extensions of the interpreted hydrothermal feeders into potential source rocks.

Michael Garagan, Director and Chief Geological Officer of Saga Metals, commented: "The 2026 maiden diamond drill program at Wolverine has successfully confirmed the presence of the target alteration assemblage in every hole drilled and has provided the first systematic look at the volcanic sequence at depth. Combined with the mapping and prospecting results, which demonstrate that the prospective units and additional pegmatite targets extend well beyond the current drill area, we have generated a substantial data set that will shape our 2027 exploration strategy and maiden Mineral Resource Estimate. We look forward to receiving the assay results, advancing the geological model and continuing our goal of proving that the Flowers River Igneous Suite contained within the Wolverine project, the largest peralkaline intrusive volcanic complex in Labrador, can compete and rival the likes of Torngat Metals' Strange Lake Rare Earth Project and Critical Metals Corp.'s Tanbreez Rare Earth Project."

Qualified Person

Dr. A. Miller, P. Geo., PEGNL, is an Independent Qualified Person as defined under National Instrument 43-101 and has reviewed and approved the technical information disclosed in this news release.

About SAGA Metals Corp.

SAGA Metals Corp. is a North American mining company focused on the exploration and discovery of a diversified suite of critical minerals that support the North American transition to supply security. The 100% owned Radar Ti-V-Fe Project comprises 24,175 hectares and entirely encloses the Dykes River intrusive complex, mapped at 160 km² on the surface near Cartwright, Labrador. Exploration to date, including 24,641 m of drilling in the Hawkeye and Trapper zones, has confirmed a large, mineralized layered mafic intrusion hosting vanadiferous titanomagnetite (VTM) and ilmenite mineralization with consistently uniform grades of titanium, vanadium and iron.

The 100% owned Wolverine Heavy Rare Earth Element Project in Labrador, is a near-surface REE system hosted within peralkaline volcanic rocks that shares petrological similarities with the intrusion-hosted Tanbreez, Strange Lake deposits and the stratiform Brockman (Hastings) REE deposit, Western Australia. Historic drilling on the Wolverine prospect identified consistent mineralization with assays up to 2.03% TREO including approximately 28% HREO. Large scale potential is supported by 26 km2 of exposed mineralization tuff at surface with about 5% of the prospective unit drilled to date. In addition, grab sample assays of pegmatite hosted in peralkaline granite returned up to 21.6% TREO.

The 100% owned Double Mer Uranium Project covers 25,600 hectares and features uranium radiometrics that highlight an 18 km east-west trend, with a confirmed 14 km section producing samples as high as 0.428% U3O8. (2024 Double Mer Technical Report).

Additionally, SAGA owns the Legacy Lithium Project in Quebec's Eeyou Istchee James Bay region. This project spans 73,866 hectares and has geological attributes similar to nearby terrains currently being explored by Rio Tinto, Li-FT Power, SOQUEM, and Loyal Metals.

With a portfolio spanning key commodities critical to the clean energy future, SAGA is strategically positioned to play an essential role in securing critical minerals.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Disclaimer

This news release contains forward-looking statements within the meaning of applicable securities laws that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipates", "expects", "believes", and similar expressions or the negative of these words or other comparable terminology. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties.

QUINCY, Mass., Oct. 21, 2026 /PRNewswire/ -- Granite Telecommunications confirmed today that a former employee, George Meegan, has been indicted on criminal charges including larceny, filing a false tax return and money laundering. The charges arise from a Granite internal investigation which revealed that Meegan had used his company credit card to purchase gift cards which he falsely claimed he was donating to local charities as part of the company's charitable programs.

Granite has donated over $400 million to charitable causes since 2002 and has consistently been recognized as one of the most philanthropic companies in Massachusetts. Granite's investigation revealed that Meegan abused a position of trust with respect to Granite's charitable activities to carry out this criminal activity. Through its investigation, Granite learned that Meegan represented to Granite that he had given the gift cards to charitable causes. In fact, Meegan kept the gift cards — worth over $225,000 — for his personal use.

Granite immediately alerted authorities after it discovered Meegan's scheme, and the company has cooperated fully with law enforcement investigators throughout their investigation.

SOURCE Granite Telecommunications, LLC

Share this article

AX6 Cobot and Live Demonstrations Highlight Epson's Expanding Automation Portfolio

LOS ALAMITOS, Calif., Oct. 21, 2026 /PRNewswire/ -- Epson Robots, the #1 SCARA robot manufacturer in the world, will showcase its expanding automation portfolio, including its first collaborative robot, the AX6, at The ASSEMBLY Show 2026, taking place in Rosemont, Illinois from Oct. 27-29, 2026, in booth #331.

"Every automation application has different safety requirements, and there is no one-size-fits-all approach," said Scott Marsic, group product manager, Epson Robots. "With the AX6 and SafeSenseTM technology, Epson is giving manufacturers more options to select the right solution for their requirements. At The ASSEMBLY Show, we look forward to demonstrating how these offerings complement our broader robotics portfolio and help manufacturers address a wide range of automation needs."

With Epson's latest automation technologies, attendees can experience live demonstrations showcasing integrated robotics, vision, and feeding solutions. The live applications will highlight practical, cost-effective solutions for real-world production environments. An educational speaking session will also focus on selecting the right automation approach for each application. Epson highlights at The ASSEMBLY Show 2026 will include:

- Speaking Engagement

- "Automation Isn't the Answer. Choosing the Right Automation Is." – Marsic will outline a practical framework for choosing the right automation strategy, from evaluating opportunities and avoiding application creep to balancing critical design considerations such as safety, robot geometry, workcell design and flexibility. The session will focus on solving the right business problem to create automation systems that are easier to implement, scale and maintain while delivering stronger productivity, reliability and long-term ROI. The session will take place Wednesday, October 28 from 2 – 2:30 p.m. at the Learning Theater.

- AX6 Collaborative 6-Axis Robot – See Epson's first collaborative robot in action, featuring a lightweight, compact footprint and intuitive no-code software designed to simplify programming and deployment. Power- and force-limiting capabilities and flexible end-of-arm options support collaborative applications where space, ease of use and fast redeployment are priorities.

- SafeSense Interactive Demo – Experience a hands-on demonstration of Epson's SafeSense technology, which uses sensors to detect when a person enters the robot's workspace, supporting safe human-robot interaction while maintaining high-performance automation.

- IntelliFlexTM Feeding System – See live demonstrations featuring Epson's latest SCARA and 6-Axis robots integrated with IntelliFlex Feeding Systems for automated part handling and assembly applications.

- Epson RC+® Development Software – Explore Epson's PC-based environment with intuitive GUI Builder for custom interfaces along with integrated vision and IntelliFlex capabilities. Developed and supported by Epson, the software is designed to simplify automation development and deployment.

The ASSEMBLY Show 2026 will take place on Oct. 27 from 4 p.m. to 7 p.m. CDT, Oct. 28 from 10 a.m. to 5 p.m. CDT and Oct. 29 from 9 a.m. to 2 p.m. CDT at the Donald E. Stephens Convention Center in Rosemont, Illinois. To learn more about Epson robot solutions at the show, stop by booth #331 or visit www.epsonrobots.com to contact a robot expert.

About Epson Robots

Epson Robots is a global leader in PC-controlled precision factory automation, with well over 250,000 units sold worldwide1 and a product line of hundreds of models of easy-to-use SCARA and 6-Axis robots based on a common PC-based platform. Building on four decades of experience, Epson Robots delivers robots for precision assembly and material handling applications in the aerospace, appliance, automotive, biotechnology, consumer product, electronics, food processing, medical device, pharmaceutical, plastics, semiconductor, and telecommunication industries. For more information, visit www.epsonrobots.com.

About Epson

Epson is a technology innovation and engineering company whose philosophy of efficient, compact and precise innovation enriches lives and helps create a better world. The company uses technology and engineering ability to implement real-world solutions in precision innovation, industrial and robotics, office and home printing, and visual and lifestyle.

Led by the Japan-based Seiko Epson Corporation, the worldwide Epson Group generates annual sales of more than JPY 1.4 trillion. corporate.epson/en/

Epson America, Inc., based in Los Alamitos, Calif., is Epson's regional headquarters for the U.S., Canada and Latin America. To learn more about Epson, please visit: epson.com. You may also connect with Epson America on Facebook (facebook.com/Epson), X (x.com/EpsonAmerica), YouTube (youtube.com/epsonamerica) and Instagram (instagram.com/EpsonAmerica).

SOURCE Epson America, Inc.

Share this article

Built on the largest risk-adjusted patient outcomes database in rehab therapy, Limber's Recovery Forecast replaces traditional single point-in-time forecasts or MCID comparisons with a 90-day outlook

PITTSBURGH, Oct. 21, 2026 /PRNewswire/ -- Limber Health, a Net Health company, today announced Recovery Forecast, the first-ever predicted outcomes trajectory solution for rehab therapy. Built into the Limber outcomes platform, Recovery Forecast maps each patient's expected path throughout care by comparing them with millions of completed assessments and applying robust risk adjustment. Available to clients this fall, this new clinical capability covers the primary MSK regions of injury.

"Current solutions show a point-in-time measurement, but rarely provide context or insight into the score," said Nirav Modi, president of Limber Health. "Recovery Forecast shows clinicians how a patient is progressing through their plan of care, so they can assess, adjust, and guide them toward the best possible improvement."

Because Limber Outcomes follows patients from evaluation through the full episode of care, the expected path stays visible between visits. At intake, the feature predicts each patient's path; then at each reassessment, clinicians compare the actual score with the prediction for real-time context. This gives clinicians an opportunity to adjust the course of care.

"Being able to predict a patient's outcome trajectory is a game changer," said Brian Kelly, Vice President of Innovation & Clinical Excellence at Ivy Health. "It transforms outcomes data into real-time clinical intelligence that enhances patient engagement, empowers proactive clinical decision-making, and ensures every patient is positioned for an optimal recovery."

A newly developed progression indicator, the Predicted Moderate Clinical Improvement (P-MCI), marks where a patient is expected to reach clinically meaningful improvement. P-MCI is already part of commercial payer quality programs. It underpins five functional improvement measures in the CMS proposed rule for the 2027 Physician Fee Schedule, with Limber Health and Patient360 as measure stewards. For more information about Limber Recovery Forecast, click here.

About Limber Health

Limber Health, a Net Health company, extends in-person musculoskeletal (MSK) care into the home with Remote Therapeutic Monitoring (RTM), Home Exercise Programs (HEP), and Limber Outcomes, which helps practices measure patient progress and predict recovery using the largest risk-adjusted patient outcomes database in rehab therapy. Limber's solutions are developed by physical therapists and physicians. Learn more at www.limberhealth.com.

About Net Health

For over 30 years, Net Health has gathered specialty knowledge shaped by human expertise and informed by patient outcomes. Today, this depth of knowledge is the foundation for an AI-native specialty platform that delivers intelligence to clinicians across the care continuum, enabling them to be present with patients during the moments that matter. Net Health is a trusted source of specialty solutions for more than 34,000 healthcare organizations, and is a portfolio company of The Carlyle Group, Level Equity, and Silversmith Capital Partners.

SOURCE Net Health Systems, Inc.

Share this article

In the news release, Input 1 Selected by The Agency Collective to Support its New AC Premium Finance Program, issued 21-Oct-2026 by Input 1, LLC over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:

Input 1 Selected by The Agency Collective to Support its New AC Premium Finance Program

New branded program gives The Agency Collective members access to premium finance technology, servicing and operational support.

WESTLAKE VILLAGE, Calif., Oct. 21, 2026 /PRNewswire/ -- The Agency Collective ("The AC") has selected Input 1 to support its premium finance technology and servicing infrastructure for a new branded program for The AC's network of more than 4,300 independent agencies.

AC Premium Finance gives participating members access to a highly advanced and competitive premium finance program. The program expands the resources available to agencies while preserving the flexibility and independence central to The AC's member model.

Previously, AC member agencies managed premium finance through individual provider relationships. The new program gives members access to a shared option across the network, creating a unified customer experience for policyholders who choose to finance their premiums.

"The AC wanted to give its members a premium finance option built specifically for its network while maintaining the unique experience developed by The AC. We were able to deliver this through our unique private-label model," said Jim Nowak, Regional Vice President of Input 1.

"We were looking for a partner that understood the needs of independent agencies and could support the kind of program we wanted to bring to our members," said Randy Crane, Chief Operations Officer, The AC. "Input 1 gave us the flexibility, experience, and support to build AC Premium Finance around the way our network does business."

About The AC

The AC provides independent insurance agencies with access to carrier relationships, resources, business solutions and opportunities designed to help them grow while maintaining their independence. Today, more than 4,300 agencies across 48 states utilize The AC.

About Input 1

Input 1 provides insurance-focused billing infrastructure, managed billing services, digital payments, and premium finance capabilities through its technology and services platform. Trusted by more than 2 million users and supporting more than $16 billion in annual insurance premiums, Input 1 helps insurance organizations manage premium billing, collection, reconciliation, payments, and premium finance across North America. For more information, visit www.input1.com.

Media Contact

Input 1 Marketing

[email protected]

(888) 882-2554

Correction: The photo has been updated.

SOURCE Input 1, LLC

Share this article

The agentic platform helps nontechnical teams save time, eliminate redundant work and deploy specialized AI agents across more than 1,000 existing applications

IRVINE, Calif., Oct. 21, 2026 /PRNewswire/ -- Asuri today announced the launch of its multi-agent enterprise AI platform, designed to help businesses move beyond copilots and deploy persistent AI workflows across complete business processes.

As AI models become more capable, the challenge for businesses is shifting from generating answers to safely giving AI the context, system access and autonomy required to perform real work.

Asuri brings those pieces into one platform.

Nontechnical teams can define a business process, connect the applications involved, assign specialized agents to different responsibilities, and control what each agent can access, recommend or execute. By coordinating work that would otherwise require employees to repeatedly move between systems, gather information and perform routine follow-ups, Asuri helps organizations save time and remove redundant manual work.

"The model itself is becoming less of the bottleneck," said Artem Bespaloff, CEO and co-founder of Asuri. "The harder problem is coordinating agents across real business systems while giving each one the right context, permissions and level of autonomy."

Unlike traditional AI assistants that primarily respond to prompts, Asuri is designed around persistent multi-agent workflows.

Asuri combines multi-agent orchestration, workflow logic, persistent context and agent-level permission controls in a single environment, with more than 1,000 integrations connecting agents to the software businesses already use.

This allows companies to automate processes across existing systems instead of replacing their technology stack, reducing repetitive administrative work and freeing employees to focus on higher-value decisions and relationships.

As part of its launch, Asuri is introducing prebuilt customer intelligence workflows that consolidate information from multiple business systems, analyze client activity against company-defined rules, and automatically alert employees to significant developments. By eliminating the need to manually track client activity across different platforms, these workflows reduce the workload on sales and research teams, helping them stay informed, identify opportunities, and focus on higher-value activities.

The same architecture can support workflows across sales, operations, finance, customer success, research and internal compliance.

Businesses can learn more and request access at Asuri.ai.

About Asuri

Asuri is a multi-agent enterprise AI platform, built by Sprouter Technologies, for persistent, governed business workflows. With more than 1,000 integrations, Asuri helps organizations connect specialized AI agents across their existing applications, reduce repetitive work, save employee time and automate processes while maintaining individual permissions, autonomy boundaries and human oversight.

For more information you can contact [email protected]

SOURCE Sprouter Technologies

Share this article